HilleVax (HLVX) Q2 2024 earnings summary

Executive summary

• Reported top-line data from NEST-IN1 Phase 2b trial for HIL-214 in infants; primary endpoint not met, no clinical benefit observed, leading to discontinuation of HIL-214 development in infants and a 40% workforce reduction.

• Exploring continued development of HIL-214 and HIL-216 in adults and business development opportunities.

• Ended Q2 2024 with $245.0 million in cash, cash equivalents, and marketable securities, down from $303.5 million at year-end 2023.

Financial highlights

• Net loss of $40.7 million for Q2 2024, compared to $27.9 million in Q2 2023; net loss of $87.5 million for the six months ended June 30, 2024, versus $54.8 million for the same period in 2023.

• Operating expenses for Q2 2024 were $43.0 million, up from $30.2 million in Q2 2023, driven by higher R&D, G&A, and $8.2 million in impairment charges.

• Research and development expenses rose to $26.6 million in Q2 2024 from $23.0 million in Q2 2023, mainly due to increased R&D headcount.

• Net loss per share was $(0.83) for Q2 2024 and $(1.79) for the six months ended June 30, 2024.

• Cash, cash equivalents, and marketable securities decreased by $58.4 million since December 31, 2023.

Outlook and guidance

• Plans to discontinue HIL-214 development in infants and focus on potential adult indications and business development for HIL-214 and HIL-216.

• Workforce reduction expected to result in $3.4 million in charges, with most recognized in Q3 2024.

• Existing cash, cash equivalents, and marketable securities expected to fund operations for at least the next 12 months.

• Workforce reduction intended to preserve capital while maintaining core capabilities.